Pharma: Other News To Note
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, and H. Lundbeck A/S, of Copenhagen, Denmark, said the FDA accepted for filing the companies' new drug application for vortioxetine for the treatment of major depressive disorder in adults. A PDUFA date of Oct. 2, 2013, is anticipated. Takeda and Lundbeck also disclosed the proposed brand name of Brintellix for vortioxetine.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter